NCT05291338View on ClinicalTrials.gov

Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

CompletedOBSERVATIONAL

Enrollment

107

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

April 1, 2023

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Doxorubicin

no optimal dosage of doxorubicin in TACE procedures (ranging from 30 to 75 mg/m2 up to a maximum of 150 mg/m2 ) according to tumor size

DRUG

Lipiodol

Lipiodol dose should be over 5 ml if tumor diameter is less than 5 cm, and the maximum dose will be 10 ml when the tumor develops to more than 5 cm in diameter.

Trial Locations (1)

Unknown

Ain Shams University hepatoma group, EL Demerdash Hospital, Cairo, Egypt., Cairo

All Listed Sponsors

lead

Rehab Werida

OTHER

NCT05291338 - Pharmacogenetic Study in Hepatocellular Carcinoma Patients. | Biotech Hunter | Biotech Hunter